InsiderTrades.com logo
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.

PSTV Insider Trading

Insider Ownership Percentage: 5.49%
Insider Buying (Last 12 Months): $82,744.90
Insider Selling (Last 12 Months): $0.00

Plus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Plus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Plus Therapeutics Share Price & Price History

Current Price: $1.36
Price Change: ▲ Price Increase of +0.07 (5.43%)
As of 12/3/2024 12:38 PM ET

This chart shows the closing price history over time for PSTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes   |   Ad
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Click here to see a unique election-year trade

Plus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2024Richard J HawkinsDirectorBuy4,000$1.50$6,000.0015,188View SEC Filing Icon  
9/11/2024Howard ClowesDirectorBuy5,000$1.34$6,700.0026,497View SEC Filing Icon  
9/10/2024Andrew John Hugh SimsCFOBuy4,098$1.27$5,204.469,815View SEC Filing Icon  
9/10/2024Marc H HedrickCEOBuy8,000$1.23$9,840.0020,425View SEC Filing Icon  
5/8/2024Andrew John Hugh SimsCFOBuy4,902$2.04$10,000.085,717View SEC Filing Icon  
5/8/2024Howard ClowesDirectorBuy9,804$2.04$20,000.1621,497View SEC Filing Icon  
5/8/2024Marc H HedrickCEOBuy12,255$2.04$25,000.2012,425View SEC Filing Icon  
11/20/2023Marc H HedrickCEOSell2,068$1.96$4,053.28170View SEC Filing Icon  
11/15/2023Robert P. LenkDirectorBuy1,000$1.77$1,770.0024,160View SEC Filing Icon  
11/13/2023Robert P. LenkDirectorBuy4,000$1.43$5,720.0023,160View SEC Filing Icon  
11/10/2023Robert P. LenkDirectorBuy2,000$1.45$2,900.0019,160View SEC Filing Icon  
11/8/2023Robert P. LenkDirectorBuy5,000$1.65$8,250.0012,961View SEC Filing Icon  
11/6/2023Robert P. LenkDirectorBuy1,395$1.50$2,092.501,961View SEC Filing Icon  
9/13/2023Howard ClowesDirectorBuy6,993$1.43$9,999.9911,693View SEC Filing Icon  
9/11/2023Greg PetersenDirectorBuy20,000$1.70$34,000.0024,166View SEC Filing Icon  
6/6/2023Howard ClowesDirectorBuy1,000$3.98$3,980.004,700View SEC Filing Icon  
5/3/2023Howard ClowesDirectorBuy2,500$3.64$9,100.003,700View SEC Filing Icon  
3/3/2023Richard J HawkinsDirectorBuy0$15,000.00$0.00View SEC Filing Icon  
6/15/2022Marc H HedrickCEOBuy333$9.75$3,246.752,238View SEC Filing Icon  
6/2/2022Howard ClowesDirectorBuy1,000$8.55$8,550.001,200View SEC Filing Icon  
4/26/2022Andrew John Hugh SimsCFOBuy200$10.05$2,010.00815View SEC Filing Icon  
4/26/2022Marc H HedrickCEOBuy333$10.35$3,446.551,738View SEC Filing Icon  
3/1/2022Andrew John Hugh SimsCFOBuy133$16.50$2,194.50View SEC Filing Icon  
See Full Table
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes   |   Ad
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Click here to see a unique election-year trade

SEC Filings (Institutional Ownership Changes) for Plus Therapeutics (NASDAQ:PSTV)

3.28% of Plus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PSTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Plus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/7/2024AIGH Capital Management LLC568,681$0.84M0.3%N/A9.977%Search for SEC Filing on Google Icon
11/15/2022Parkman Healthcare Partners LLC1,325,025$0.59M0.2%-13.6%3.943%Search for SEC Filing on Google Icon
8/8/2022Otter Creek Advisors LLC330,168$0.18M0.1%+293.5%1.465%Search for SEC Filing on Google Icon
5/13/2022Parkman Healthcare Partners LLC1,526,316$1.53M0.4%N/A6.875%Search for SEC Filing on Google Icon
5/9/2022Otter Creek Advisors LLC83,901$84K0.0%N/A0.378%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.128,323$0.25M0.0%-19.7%0.835%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC76,187$0.20M0.0%N/A0.630%Search for SEC Filing on Google Icon
8/16/2021State Street Corp34,214$88K0.0%N/A0.283%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC17,607$45K0.0%N/A0.146%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp40,524$0.10M0.0%N/A0.335%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC130,793$0.33M0.0%N/A1.082%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.712,847$1.83M0.0%+824.7%5.897%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP68,430$0.18M0.0%N/A0.566%Search for SEC Filing on Google Icon
8/11/2021Susquehanna Fundamental Investments LLC13,033$33K0.0%N/A0.108%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC18,318$37K0.0%-16.5%0.383%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC106,100$0.21M0.0%+202.7%2.220%Search for SEC Filing on Google Icon
1/29/2021Creative Planning13,856$28K0.0%N/A0.290%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC21,932$56K0.0%N/A0.459%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Plus Therapeutics logo
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More on Plus Therapeutics

Today's Range

Now: $1.36
Low: $1.30
High: $1.42

50 Day Range

MA: $1.35
Low: $1.17
High: $1.85

52 Week Range

Now: $1.36
Low: $1.12
High: $2.67

Volume

112,539 shs

Average Volume

63,680 shs

Market Capitalization

$8.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Who are the company insiders with the largest holdings of Plus Therapeutics?

Plus Therapeutics' top insider investors include:
  1. Howard Clowes (Director)
  2. Greg Petersen (Director)
  3. Robert P Lenk (Director)
  4. Marc H Hedrick (CEO)
  5. Richard J Hawkins (Director)
  6. Andrew John Hugh Macintyr Sims (CFO)
Learn More about top insider investors at Plus Therapeutics.
This company will win the AI race
From Porter & Company   |   Ad
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
You must read this new presentation from Porter Stansberry.